BenevolentAI and AstraZeneca AI pharma collaboration yields success with heart failure target
Using BenevolentAI's AI-driven drug discovery platform, the two companies have jointly identified a novel target for heart failure, which has been added to AstraZeneca’s discovery portfolio.
Discovery process
After using BenevolentAI’s platform, AstraZeneca validated it through experimentation. This is the first selected target coming out of the AstraZeneca collaboration, showing great progress in target identification.
Heart disease often involves multiple interrelated diseases, necessitating a deep understanding of potential disease drivers for each patient. Most current treatments of heart disease have a generic approach, but because of a variety of causes of heart failure, there is an unmet need for other therapies.
The approach
Scientists and technologists from both companies work side-by-side, combining BenevolentAI’s AI-driven drug discovery capabilities with AstraZeneca’s disease-specific expertise.
Regina Fritsche Danielson, SVP and Head of Research and Early Development at AstraZeneca emphasised the importance of this collaboration: “Our ongoing partnership with BenevolentAI has been instrumental in uncovering new insights into complex diseases. Heart Failure represents a critical therapeutic area, and we are committed to advancing innovative solutions.”
Hear more about BenevolentAI at the 2024 PING Conference
Nicola Richmond, VP of AI at BenevolentAI, will be speaking at this year's PING Conference - AI in Pharma: Threat or Opportunity?. Other speakers include representatives from Healx, Health-Equity.AI, 7bridges, Ignota Labs and others.